Weixiao Sha

Merck · company speakers →

focused on findings involving M0324, an antibody-based construct designed to activate the CD40 immune signaling pathway, but only in the presence of high MUC1 levels in the vicinity.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

AACR Drug Discovery and Development (AACR D3)

21 July 2026 Boston, United States “M0324: Agonist Immunomodulator in MUC1-expressing Cancers”

Sourcing speakers for your event?

Browse the speaker directory →